Top Stock Gainers: Rising Dragon Acquisition Corp. (NASDAQ: RDAC) and Other Notable Market Movers

• Clinical-trial news was the clearest company-specific catalyst, sending shares of Merck & Co., Inc. (NYSE: MRK) sharply higher.
• The surge in Rising Dragon Acquisition Corp. (NASDAQ: RDAC) appeared more consistent with low-float SPAC volatility than with a newly announced fundamental development.
• Gains in Carvana Co. (NYSE: CVNA), NuScale Power Corporation (NYSE: SMR), and HubSpot, Inc. (NYSE: HUBS) reflected a combination of rebounds and sector rotation rather than a single common market catalyst.

Rising Dragon Acquisition Corp. (NASDAQ: RDAC) rose 50.09% to close at $8.78, up from $5.85 in the previous session. Approximately 16.26 million shares traded, compared with a normal daily volume measured in the thousands. The stock traded as high as $22.28 before surrendering most of its intraday gain, demonstrating the extreme volatility associated with its limited public float.

Rising Dragon Acquisition Corp. (NASDAQ: RDAC) is a special-purpose acquisition company seeking to complete a previously announced business combination. Its shareholders approved amendments allowing the completion deadline to be extended monthly as far as October 15, 2027, subject to the required trust-account contributions. Significant share redemptions have reduced the public float, which can amplify price movements when trading volume rises.

Merck & Co., Inc. (NYSE: MRK) climbed 12.62% to close at approximately $152.20, with trading volume of about 32.55 million shares. The rally in Merck & Co., Inc. (NYSE: MRK) had a clearly identifiable catalyst. Merck & Co., Inc. (NYSE: MRK) and Moderna, Inc. (NASDAQ: MRNA) announced that the Phase 3 INTerpath-001 trial met its primary recurrence-free-survival endpoint and a key distant-metastasis-free-survival endpoint. The trial evaluated the individualized mRNA therapy intismeran autogene in combination with Keytruda in patients with surgically removed, high-risk melanoma. 

Carvana Co. (NYSE: CVNA) advanced approximately 8.45% to $70.44 on volume of roughly 12.34 million shares. The price is presented on a split-adjusted basis following the company’s five-for-one forward stock split, which took effect in May 2026. Carvana Co. (NYSE: CVNA) had fallen about 7.3% in the previous session amid concerns involving a federal investigation of major investor Mark Walter, making the August 19 increase partly a rebound from that decline rather than evidence of a new corporate development.

NuScale Power Corporation (NYSE: SMR) increased approximately 7.52% to $9.29, with trading volume of about 36.05 million shares. Investor interest in small modular reactors and their potential use in data centers and industrial facilities may have supported the shares. However, no major same-day announcement from NuScale Power Corporation (NYSE: SMR) was identified, so the gain should not be directly attributed to a competitor’s supply-chain activities.

HubSpot, Inc. (NYSE: HUBS) advanced approximately 6.79% to $241.65 on volume of about 2.18 million shares. The move occurred alongside gains in several enterprise-software stocks, suggesting that sector rotation and bargain buying after earlier software-sector weakness contributed to the increase. HubSpot, Inc. (NYSE: HUBS) had also recently reported second-quarter revenue of $911.7 million, representing year-over-year growth of approximately 20%, although its subsequent quarterly revenue guidance was below analysts’ expectations. 

Overall, these gains did not arise from a single market theme. Positive Phase 3 clinical data clearly drove the advance in the pharmaceutical company, while low-float trading dynamics were likely important for the SPAC. The other stocks appeared to benefit from rebounds, industry enthusiasm, or investor rotation, and those explanations should be presented as market interpretations rather than confirmed company-specific catalysts.